Morphological Transformation Induced by Activation of the Mitogen-activated Protein Kinase Pathway Requires Suppression of the T-type Ca2+ Channel*

Matthew W. StrobeckDagger , Masaru OkudaDagger , Hiroshi Yamaguchi§, Arnold Schwartz§, and Kenji FukasawaDagger

From the Dagger  Department of Cell Biology and § Institute of Molecular Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0521

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transformation of fibroblasts by various oncogenes, including ras, mos, and src accompanies with characteristic morphological changes from flat to round (or spindle) shapes. Such morphological change is believed to play an important role in establishing malignant characteristics of cancer cells. Activation of the mitogen-activated protein kinase (MAPK) pathway is a converging downstream event of transforming activities of many oncogene products commonly found in human cancers. Intracellular calcium is known to regulate cellular morphology. In fibroblasts, Ca2+ influx is primarily controlled by two types of Ca2+ channels (T- and L-types). Here, we report that the T-type current was specifically inhibited in cells expressing oncogenically activated Ras as well as gain-of-function mutant MEK (MAPK/extracellular signal-regulated kinase (ERK) kinase, a direct activator of MAPK), whereas treatment of ras-transformed cells with a MEK-specific inhibitor restored T-type Ca2+ channel activity. Using a T-type Ca2+ channel antagonist, we further found that suppression of the T-type Ca2+ channel by the activated MAPK pathway is a prerequisite event for the induction and/or maintenance of transformation-associated morphological changes.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Oncogenically transformed cells display many properties that are not observed in normal cells. One such transformed phenotype is the change in cell morphology. For example, the introduction of oncogenically activated Ras into fibroblasts induces a round-up or spindle-shaped morphology, which in turn disrupts the regulatory mechanisms controlling cell-cell contact and cell-substratum adhesivity and, thus, is believed to contribute to malignant (metastatic) phenotypes of cancer cells (reviewed in Ref. 1). Intracellular calcium is known to play an important role in establishment of cellular morphology. Early studies showed the calcium sensitivity of actin and actin-binding proteins (reviewed in Ref. 2), major cytoskeletal components (reviewed in Refs. 3 and 4). Moreover, calcium ions regulate the formation of actin bundles and networks (5, 6). It has also been shown that ectopic expression of calmodulin, a major intracellular Ca2+-binding protein (reviewed in Ref. 7) or administration of calmodulin-antagonists disrupts Ca2+ homeostasis, leading to changes in cell morphology and cytoskeleton organization (8). Microinjection of villin, a Ca2+-regulated F-actin bundling and nucleating protein (reviewed in Refs. 9 and 10), into NIH 3T3 cells results in disruption of the stress fiber networks, leading to morphological changes (11). These findings indicate that calcium signaling is important for maintaining proper cell morphology.

In fibroblasts, two major voltage-dependent Ca2+ channels are present: L (long-lasting, large conductance)-type and T (transient)-type channels (12, 13). L- and T-type channels are distinguished by differences in their electrophysiological and pharmacological properties (reviewed in Refs. 14-19). The L-type channel requires strong depolarization for activation, shows high sensitivity to dihydropyridines, and inactivates slowly. In contrast, the T-type is a rapidly inactivating channel activated by weak depolarizations and is resistant to organic blockers of L-type channels but relatively sensitive to mibefradil. Because of the low fluctuation of membrane potential in fibroblasts, T-type channels are thought to impart a greater influence on fibroblast physiology than L-type (13, 20, 21). In Swiss 3T3 fibroblasts transformed by various oncogenes (i.e., v-ras, v-fms, or polyoma virus middle T oncogenes), T-type channel currents have been shown to be specifically suppressed (12).

Ras is a plasma membrane-localized GDP/GTP-binding protein that is active in the GTP-bound state and functions as an extracellular mitogenic signal transducer. Activating mutations of Ras results in constitutive signaling to downstream elements, leading to cellular transformation (reviewed in Refs. 22 and 23). To date, three major effector pathways of Ras have been characterized in detail: the mitogen-activated protein kinase (MAPK)1 pathway, the phosphatidylinositol 3-kinase pathway, and the Ral/GDS pathway (most recently reviewed in Refs. 24 and 25). In the MAPK pathway, activated Ras promotes the movement of Raf to the plasma membrane where it becomes a functional kinase (26-31). Raf then phosphorylates MAPK kinases (MEK) (32-36), which in turn activates MAPK through phosphorylation (37). In the phosphatidylinositol 3-kinase pathway, Ras binds and activates phosphatidylinositol 3-kinase (38, 39), which results in activation of a variety of effector molecules including Akt/PKB, Vav, SOS, and GRP1 (40-42). In the Ral/GDS pathway, Ras binds and activates Ral/GDS (43-45), which in turn activates effectors such as CDC42 and Rac1 (46, 47).

Using various Ha-Ras effector loop mutations (39, 48-50), we first attempted to identify which of the downstream effector pathway(s) of Ras are responsible for inhibiting the T-type Ca2+ channel current. We found that Ras mutants lacking the ability to activate the MAPK pathway failed to inhibit T-type Ca2+ channel current, whereas Ras mutants that activate only the MAPK pathway efficiently inhibit T-type channel activity. Moreover, the introduction of the constitutively active MEK results in inhibition of the T-type Ca2+ channel current. By use of the T-type channel blocker, mibefradil, we further found that the suppression of the T-type Ca2+ channel is essential for the induction and/or maintenance of spindle-shape transformation morphology in fibroblasts.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells, Plasmids, and Transfection-- Swiss 3T3 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/ml), and streptomycin (100 µg/ml) (this medium will be referred to as complete medium hereafter) at 37 °C in 10% CO2. Plasmids were transfected by the calcium phosphate method previously described (51). Approximately 1 × 106 cells were plated in 100-mm dishes 24 h before transfection. The Swiss 3T3 cells were transfected with the following Ras mutant plasmids: 12V, 12V35S, 12V37G, 12V40C with pKOneo plasmid encoding a neomycin-resistance gene in a 20:1 molar ratio. The ras mutant genes were tagged with the hemagglutinin (HA) epitope, and expression was controlled by the cytomegalovirus promoter. Swiss 3T3 cells were also transfected with a plasmid encoding a gain-of-function MAPK kinase (MEK) mutant gene (Delta N3-S218E-S222D (52)). Transfected cells were selected in medium supplemented with G418 (400 µg/ml). In ras mutant-transfected cells, G418-resistant colonies were pooled. For cells transfected with the MEK mutant, G418 resistant colonies were subcloned.

Electrophysiological Analysis-- Ba2+ currents through endogenous voltage-dependent Ca2+ channels expressed in cells stably transfected with 12V, 12V35S, 12V37G, 12V40C, and MEK were recorded using the whole cell configuration of the patch-clamp technique (53). All recordings were done at room temperature. Cells were incubated in a bath solution containing (20 mM BaCl2, 135 mM tetraethylammonium chloride, 10 mM HEPES (pH 7.4)). The patch electrodes were pulled and fire polished, after which they had an electrical resistance of ~3 megaohms when filled with an internal solution containing (140 mM L-aspartate, 5 mM EGTA, 5 mM pyruvate Na+, 5 mM oxaloacetate, 5 mM creatine, 10 mM HEPES/CsOH (pH 7.4)). Currents were recorded using an Axopatch 200A patch-clamp amplifier and analyzed using the pClamp (version 6.02, Axon instruments, Inc.) software. Whole cell capacitive transients were compensated on-line, and linear leakage currents were cancelled using a P/4 subpulse protocol. The data were filtered at 2 kHz and digitized at 10 kHz via a Lambaster interface (Axon instruments Inc., Burlingame, CA). L-type currents were elicited by ten 10-mV depolarizing test pulses between -20 to +70 mV from a holding potential of -30 mV, where T-type was completely inactivated. T-type currents were evoked by using ten 10-mV step pulses from -40 to +50 mV, with a holding potential of -80 mV in the presence of 1 µM nifedipine. Identity of L- and T-type currents were confirmed by their sensitivity to nifedipine and mibefradil, respectively.

Immunoblot Analysis-- To prepare cell lysates, cells were washed twice with PBS and lysed in SDS-Nonidet P-40 lysis buffer (1% SDS, 1% Nonidet P-40, 50 mM Tris (pH 8.0), 150 mM NaCl, 4 mM Pefabloc SC (Roche Molecular Biochemicals), 2 µg/ml leupeptin, 2 µg/ml aprotinin). The lysates were sonicated, boiled for 5 min, and then centrifuged at 4 °C for 10 min at 20,000 × g. The lysates were further denatured for 5 min at 95 °C in sample buffer (2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% beta -mercaptoethanol, 0.01% bromphenol blue). The proteins were fractionated by SDS-polyacrylamide gel electrophoresis and transferred onto Immobilon-P membranes (Millipore). The membranes were blocked with TBST (20 mM Tris HCl (pH 7.6), 137 mM NaCl, and 0.2% Tween 20) with 5% (w/v) dry milk) at room temperature (20-22 °C). After multiple washes with TBST, the membranes were incubated with primary polyclonal antibodies: anti-HA (clone Y-11, Santa Cruz), anti-MEK-1 (clone 12-B, Santa Cruz), or anti-phosphorylated MAPK (New England Biolab). The blots were then washed thoroughly with TBST and then incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG for 1 h at room temperature. The antibody-antigen complex was detected by the enhanced chemiluminescence procedure (ECL, Amersham Pharmacia Biotech).

Morphological Transformation Assay-- Because of the p53-dependent toxicity associated with overexpression of Ras, Swiss 3T3 cells stably transfected with human p53 mutant (Val at amino acid residue 143 was changed to Ala) were transiently transfected with ras mutant plasmids (25 µg/100-mm plate). Cells were then incubated in media supplemented with 1% FBS and appropriate Ca2+ channel antagonists. Five to 7 days after transfection, cells were fixed, and either Giemsa-stained or processed for immunostaining as described below.

Indirect Immunofluorescence-- Transiently transfected cells grown on slides with 1% FBS and respective Ca2+ channel antagonist were washed with PBS and then fixed with 10% formalin. The cells were then washed with PBS and permeabilized with 1% Nonidet P-40 in PBS for 5 min at room temperature. The cells were incubated with blocking solution (10% normal goat serum in PBS) for 1 h and probed with an anti-HA monoclonal antibody (Roche Molecular Biochemicals) for 1 h. The antibody-antigen complexes were detected with rhodamine-conjugated goat anti-mouse IgG antibody. After 30 min of incubation at room temperature, the samples were washed three times with PBS. Cells were also stained with 4',6-diamidino-2-phenylindole (DAPI) DNA dye for visualization of nuclei.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Electrophysiological Dissection of Ras Downstream Effectors in T-type Ca2+ Channel Inhibition-- To elucidate which downstream Ras signaling pathway(s) is involved in suppression of the T-type Ca2+ channel, Swiss 3T3 cells were transfected with four different Ha-ras mutants (12V, 12V35S, 12V37G, 12V40C) (39, 48-50). The 12V35S (Gly-12 right-arrow Val,Thr-35right-arrow Ser) mutant retains the Raf-1 binding site and thus can activate the Raf-1/MEK/MAPK pathway. The 12V37G (Gly-12 right-arrow Val,Glu-37 right-arrow Gly) and 12V40C (Gly-12 right-arrow Val,Tyr-40 right-arrow Cys) mutants were identified by their ability to signal downstream effectors via a Raf-independent pathway. The downstream effector activated by the 12V37G mutant is the Ral/GDS pathway and that activated by the 12V40C mutant is the phosphatidylinositol 3-kinase pathway (48). Swiss 3T3 cells transfected with these mutants tagged with influenza virus HA epitope were pooled and selected, and expression of the Ras mutants were examined by immunoblot analysis using an anti-HA monoclonal antibody (Fig. 1). All pooled cells expressed similar levels of transfected Ras proteins.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 1.   Immunoblot analysis of Ha-Ras (H-Ras) effector mutant expression in pooled Ha-ras-transfectants. Cell lysates prepared from control Swiss 3T3 cells (lane 1) and cells transfected with 12V (lane 2), 12V35S (lane 3), 12V37G (lane 4), and 12V40C (lane 5) ras effector mutants were resolved in 12% SDS-polyacrylamide gel electrophoresis. The expression of transfected Ras mutant proteins were detected with anti-HA polyclonal antibody (clone Y-11, Santa Cruz).

Calcium channel currents were measured in the mutant Ras-expressing cells by the whole-cell patch-clamp technique using Ba2+ as the external charge carrier. Electrophysiological dissection of Ca2+ channels required that we take advantage of the different voltage dependence of channel gating between the L- and T-type channels. L-type currents were recorded using a holding potential of -30 mV, a voltage in which T-type channels are inactivated and 10-mV step pulses from -20 mV to +70 mV. Representative Ba2+ current (IBa) traces of the control cells as well as 12V, 12V35S, 12V37G, and 12V40C Ras mutant-expressing cell lines are shown in Fig. 2 (columns A and B), and the corresponding current-voltage relationships of peak IBa density are shown in column C. L-type currents were detected in all the cell lines tested. The average L-type current density for control Swiss 3T3 cells was 3.21 ± 0.58 pA/pF (n = 9) and 2.82 ± 0.37 pA/pF (n = 12) for 12V, 2.33 ± 0.51 pA/pF (n = 8) for 12V40C, 1.68 ± 0.34 pA/pF (n = 12) for 12V35S, and 2.20 ± 0.37 pA/pF (n = 9) for 12V37G (Fig. 3). The L-type channel current peaked at +30 mV, and there was no significant difference in the voltage dependence among the controls and mutant Ras expressors.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Whole cell currents recorded from the control Swiss 3T3 cells and cells expressing H-ras effector domain mutants. A, representative L-type Ca2+ channel currents. Currents were elicited by a 500-ms depolarizing pulse to +30 mV from a holding potential of -30 mV. B, representative T-type Ca2+ channel currents. Currents were evoked by a depolarizing pulse to +10 mV from a holding potential of -80 mV in the presence of 1 µM nifedipine. C, current density-voltage relationships for L-type (closed circle) and T-type (open circle) Ca2+ channels.


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Current densities of L- and T-type Ca2+ channels of the control Swiss 3T3 cells and Ha-Ras effector domain mutant-expressing cells. The current density of each cell line was calculated from the results shown in Fig. 2 and presented as mean ±S.E. The statistical significance was analyzed using the Student's t test. The decrease of T-type Ca2+ currents in 12V and 12V35S Ras mutant-expressing cells is statistically significant (p < 0.05) as indicated by asterisks.

To isolate T-type current, Ba2+ currents were elicited from a holding potential of -80 mV in the presence of the L-type channel blocker, nifedipine (1 µM). The control cells elicited a T-type peak IBa with a current density of 0.62 ± 0.10 pA/pF (n = 5). The 12V37G mutant line had a current density of similar amplitude (0.55 ± 0.14 pA/pF (n = 5)), whereas the 12V40C line displayed a slightly higher T-type current density (0.87 ± 0.12 pA/pF (n = 8)). The 12V mutant had a T-type current density of 0.008 ± 0.003 pA/pF (n = 7) that was significantly less than that of the control (p < 0.001). Similar to 12V, diminished T-type current was observed in the 12V35S expressor, which had a T-type current density of peak IBa of 0.005 ± 0.003 pA/pF (n = 12), which is also significantly less than that of the control (p < 0.001). The threshold current for the L-type channel activation in both the mutants and control cells was approximately -10 mV (Fig. 2, column C). The T-type currents in the control, 12V37G, and 12V40C cells were activated approximately at a threshold of -30 mV and peaked at +10 mV with no significant difference in their voltage dependence (Fig. 2, column C). The absence of T-type currents in both 12V- and 12V35S- expressing cells suggests that the activation of the MAPK pathway may be responsible for suppression of T-type Ca2+ channel activity.

Mibefradil is a T-type-selective Ca2+ channel antagonist (54, 55). As such, we sought to determine the sensitivity of endogenous T-type Ca2+ channels to mibefradil in Swiss 3T3 cells. The treatment of Swiss 3T3 cells with 1 µM mibefradil caused approximately 50% reduction in T-type Ca2+ channel currents (Fig. 4). In the presence of 3 µM mibefradil, T-type Ca2+ channel currents were completely abolished (Fig. 4), whereas there was no change in L-type channel currents (data not shown). Similar results have been previously reported for the recently cloned alpha 1H T-type Ca2+ channel from heart (56).


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 4.   Dose-dependent inhibition of T-type Ca2+ channels in Swiss 3T3 cells by mibefradil. Mibefradil was administered to Swiss 3T3 cells by its sequential addition to the bath solution from 0, 1, and 3 µM in the presence of 1 µM nifedipine. Upon each dose change of mibefradil, cells were voltage-clamped with a holding potential of -80 mV, and a 150-ms step pulse to +10 mV was applied.

Activation of the MAPK Pathway Is Responsible for Inhibition of T-type Ca2+ Channels-- To test whether the activation of the MAPK pathway is responsible for inhibition of the T-type Ca2+ channel, Swiss 3T3 cells were stably transfected with a gain-of-function MEK mutant (Delta N3-S218E-S222D (52)). The expression of this MEK mutant results in constitutive activation of MAPK (52). The G418-resistant colonies were subcloned (3T3/MEK1 and -2), and subjected to immunoblot analysis for expression of MEK (Fig. 5A). Both 3T3/MEK1 and -2 expressed higher levels of MEK than the control Swiss 3T3 cells that were transfected with a vector plasmid. The 3T3/MEK1 and -2 cell lines were further tested for activation of MAPK by immunoblot analysis using anti-phosphorylated (activated) MAPK antibody (Fig. 5B). As expected, activated MAPK was present in both MEK-transfected cell lines.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 5.   Generation of Swiss 3T3 cells stably transfected with a gain-of-function MEK mutant. The G418-resistant colonies from cells transfected with either vector plasmid or a MEK mutant plasmid (Delta N3-S218E-S222D) were subcloned. The control Swiss 3T3 cells and two MEK-transfected cell lines (3T3/MEK1 and 3T3/MEK2) were analyzed by immunoblot analysis using anti-MEK1 polyclonal antibody (clone 12-B, Santa Cruz) (A) and anti-phosphorylated MAPK (MAPK-P) polyclonal antibody (New England Biolabs) (B). NS, non-specific band.

The 3T3/MEK1 and 2 cell lines were tested electrophysiologically. Similar to 12V and 12V35S-expressing cell lines, the 3T3/MEK1 cells exhibited an L-type current density of 3.3 ± 0.39 pA/pF (n = 11) and a T-type density of 0.005 ± 0.003 pA/pF (n = 8). The latter was significantly less (p < 0.001) than control cells (Fig. 6D). We obtained similar recordings in the 3T3/MEK2 cells (data not shown). To further show that activation of the MAPK pathway is responsible for inhibition of T-type channels in ras-transformed cells, Swiss 3T3 cells expressing the 12V Ras mutant were pretreated with the MEK-specific inhibitor, PD98059 (57, 58) for 24 h. We found that the T-type Ca2+ channel currents recovered to the levels similar to that of control Swiss 3T3 cells (Fig. 6, column B) with a current density of 0.67 ± 0.2 pA/pF (n = 6) after PD98059 treatment (Fig. 6D). Thus, we conclude that activation of the MAPK pathway is responsible for the T-type Ca2+ channel depression in ras-transformed cells.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 6.   Activation of the MEK-MAPK pathway is essential for inhibition of T-type Ca2+ channels in ras-transformed cells. a, whole cell currents from Swiss 3T3 cells expressing gain-of-function mutant MEK (3T3/MEK1) as well as ras-transformed Swiss 3T3 cells treated with 75 µM MEK-specific inhibitor (PD98059) were recorded for L-type Ca2+ channels as described in the legend to Fig. 2A. B, whole cell currents from the 3T3/MEK1 line as well as ras-transformed Swiss 3T3 cells treated with PD98059 were recorded for T-type Ca2+ channels as described in the legend for Fig. 2B. C, current-voltage relations for peak density of L-type (closed circle) and T-type (open circle) Ca2+ channels. D, current densities of L- and T-type Ca2+ channels from the 3T3/MEK1 line and PD98059-treated ras-transformed Swiss 3T3 cells were elucidated from the results shown in A and B and presented as mean ±S.E. The statistical significance was analyzed using a Student's t test. The decrease of T-type Ca2+ currents in 3T3/MEK1 is statistically significant (p < 0.05) as indicated by an asterisk.

Inhibition of T-type Ca2+ Channels Induces Morphological Transformation-- Activation of the MAPK pathway is common in cells transformed by many oncogene products and frequently observed in cancer cells (most recently reviewed in Ref. 59). Accordingly, we examined whether inhibition of the T-type Ca2+ channel by the MAPK pathway would have a role in cellular transformation. It has been shown that Swiss 3T3 cells are transformed efficiently with oncogenically activated Ras (Ras 12V) when co-transfected with mutant p53 (60, 61). Moreover, overexpression of oncogenically activated Ras induces cell cycle arrest and cell death in a p53-dependent manner (62-64). We therefore decided to use the Swiss 3T3 cell line stably transfected with the dominant negative mutant p53 (V143A), 3T3/p53(V143A). We found that the expression of mutant p53 did not affect the overall Ca2+ channel activity because the 3T3/p53(V143A) cells exhibited both L- and T-type Ca2+ channel currents similar to those of control Swiss 3T3 cells (data not shown). We then transiently transfected 3T3/p53(V143A) cells with the following Ras effector mutants: 12V, 12V37G, 12V40C, and 12V37G + 12V40C. The transfected cells were incubated under low growth conditions (1% serum) for ~7 days. As expected, 12V-transfected cells showed a spindle morphology typical of transformed cells (Fig. 7, panel a). In contrast, none of the cells transfected with 12V37G, 12V40C, or 12V37G + 12V40C showed such morphological changes (Fig. 7, panels e, i, and m). The transfected cells in parallel were treated with 1 µM nifedipine. Nifedipine treatment (inhibition of L-type Ca2+ channels) did not affect cell morphology; 12V-transfected cells showed spindle morphology (panel b), whereas cells transfected with 12V37G, 12V40C, or 12V37G + 12V40C retained a flat morphology (panels f, j, and n). Thus, the L-type Ca2+ channel does not play a role in induction and/or maintenance of transformed morphology. In addition, the 12V-transfected cells showed a spindle-like morphology in the presence of 3 µM mibefradil (selective inhibition of T-type channels (panel c). However, when cells transfected with 12V37G, 12V40C, and 12V37G + 12V40C were treated with 3 µM mibefradil, the cells became morphologically transformed, similar to the 12V-transfected expressing cells (panels g, k, and o). Consistent with the finding that inhibition of L-type channels does not affect cell morphology, co-treatment of cells with 3 µM mibefradil and 1 µM nifedipine gave similar results with mibefradil treatment alone (panels d, h, l, and p).


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 7.   Photomicrographs of 3T3/p53(V143A) cells transiently transfected with ras mutants. The 3T3/p53(V143A) cells were transfected with 12V, 12V37G, 12V40C, and 12V37G + 12V40C. Two days after transfection, cells were split into four culture dishes and fed with media containing 1% FBS. Plates from each transfection were treated with 1 µM nifedipine (panels b, f, j, and n), 3 µM mibefradil (panels c, g, k, and o), and nifedipine (1 µM) + mibefradil (3 µM) (panels d, h, l, and p). Five days after cell splitting, cells were fixed, Giemsa-stained, and examined under a microscope. Magnification, 400×.

To confirm whether the morphologically transformed cells express the transfected Ras mutants, 3T3/p53(V143A) cells transfected with 12V, 12V35S, 12V37G, and 12V40C were fixed and subjected to immunostaining using anti-HA antibody. The cells expressing transfected 12V or 12V35S Ras mutants are spindle-shaped (Fig. 8, panels a and c), whereas cells expressing transfected 12V37G and 12V40C mutants show a flat morphology (panels e and g). By treatment of 12V37G- and 12V40C-transfected cells with 3 µM mibefradil, cells acquired a spindle like morphology (panels f and h). These results demonstrate that inhibition of the T-type channel, but not the L-type channel, is essential for induction and/or maintenance of morphological transformation.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 8.   Immunofluorescence analysis of cells transiently transfected with ras mutants. Swiss 3T3 cells were transfected with 12V, 12V35S, 12V37G, and 12V40C. Two days after transfection, cells were split into two culture dishes and fed with media containing 1% FBS. One plate from each transfection was treated with 3 µM mibefradil (panels b, d, f, and h and b', d', f', and h'), and another plate was untreated (panels a, c, e, and g and a', c', e', and g'). Five days after splitting, cells were fixed and processed for immunostaining with anti-HA antibody (panels a-h). Cells were also counter-stained with 4',6-diamidino-2-phenylindole (DAPI) (panels a'-h'). Magnification, 400×.

Requirement of Other Ras Effectors in Addition to the MAPK Pathway for Morphological Transformation-- Under a serum-starved condition, normal cells become arrested at resting state (G0). It has been shown that expression of 12V, 12V35S, 12V37G, and 12V40C Ras mutants drives cells to enter mitotic cycling in a serum-independent manner (50). The findings, in which 12V37G- or 12V40C-transfected cells become morphologically transformed under serum-starved condition in the presence of the T-type Ca2+ channel inhibitor, raises two possibilities: 1) cell cycling may be required for morphological transformation by inhibition of T-type channels, and 2) other downstream effector(s) of Ras may be required for morphological transformation in addition to inhibition of T-type Ca2+ channels. To test this, we treated normal Swiss 3T3 cells with 3 µM mibefradil under optimal growth conditions (in the presence of 10% FBS) (Fig. 9). We found that the mibefradil-treated cells retained a flat morphology similar to untreated cells, suggesting that mere cell cycling does not allow for morphological transformation even if the T-type channel is blocked (Fig. 9, panel b). Because Ras targets multiple effectors, in addition to the inhibition of the T-type channels by the MAPK pathway, one or more of those downstream effectors of Ras other than the pathways examined in this study appear to be required for induction/maintenance of morphological transformation.


View larger version (60K):
[in this window]
[in a new window]
 
Fig. 9.   Inhibition of T-type Ca2+ channels does not induce morphology change in exponentially growing Swiss 3T3 cells. Swiss 3T3 cells growing in complete media were treated with mibefradil (3 µM) for 48 h, then fixed and Giemsa-stained. The treatment of Swiss 3T3 cells with 3 µM mibefradil resulted in almost complete inhibition of T-type channels (Fig. 4). There was no morphological change in the mibefradil-treated cells (panel b) in comparison with untreated control cells (panel a), suggesting that the inhibition of T-type channels alone does not induce changes of cell morphology. Magnification, 400×.

Suppression of T-type Ca2+ Channel Activity by Activation of the MAPK Pathway Is Essential for Morphological Transformation-- By use of MEK-specific inhibitor PD98059, we directly examined whether the suppression of the T-type Ca2+ channel by activation of the MAPK pathway is important for maintenance of a transformed morphology. Swiss 3T3 cells stably transfected with oncogenically activated Ras (12V Ras) were treated with 75 µM PD98059 for 24 h and examined under a light microscope. PD98059 treatment (thus inactivation of the MAPK pathway) resulted in reversion of the transformed morphology to a flat morphology similar to normal Swiss 3T3 cells (Fig. 10, panel b). Together with the findings that PD98059 treatment recovers the T-type Ca2+ channel activity (Fig. 6, column b), our observations demonstrate that inhibition of T-type Ca2+ channels by activation of the MAPK pathway is critical for maintaining morphological transformation.


View larger version (70K):
[in this window]
[in a new window]
 
Fig. 10.   Inhibition of the MEK-MAPK pathway by PD98059 reverts cell morphology of ras (12V)-transformed cells. Swiss 3T3 cells transformed with ras (12V) were treated with the MEK inhibitor, PD98059 (75 µM) for 24 h. Cells were then fixed, Giemsa-stained, and examined under a light microscope. Magnification, 400×.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Calcium plays an important role in a variety of fundamental cellular events, including muscle contraction, hormone secretion, gene expression, cell cycle control, and cell morphology (65). The levels of intracellular Ca2+ are differentially regulated depending on the cell type. In fibroblasts, L- and T-type Ca2+ channels are present. Fluctuations or oscillations of membrane potential is generally low enough to activate T-type but not L-type channels. Thus, the T-type channel likely plays a predominant role in regulating intracellular concentration of Ca2+ in fibroblasts (13). It has been shown that the T-type Ca2+ channel current, but not the L-type, are inhibited in cells transformed by various oncogenes including ras (12). In this study, we show that activation of the MAPK pathway is responsible for the inhibition of T-type channels in ras-transformed cells. Because MAPK activation is a converging point of the transforming functions of various oncogene products (reviewed in Refs. 59 and 66), specific inhibition of T-type channels in cells transformed by various oncogenes, shown by Chen et al. (12), is likely mediated by the activation of the MAPK pathway.

One of the major transformation-associated phenotypes induced by activation of the MAPK pathway is change of cell shapes (from flat to round-up or spindle-shaped morphology). For example, ras-transformed cells show a marked morphological reversion from spindle-shaped to flattened upon exposure to the MEK-specific inhibitor. Such morphological changes are believed to play a critical role in malignant transformation. By use of the T-type channel blocker, mibefradil, we investigated the role of T-type Ca2+ channel inhibition in cellular transformation. We found that loss of T-type Ca2+ channel activity is essential for induction and/or maintenance of morphological transformation. However, abrogation of T-type Ca2+ channel activity alone does not appear to be sufficient for inducing morphological changes, because treatment of either serum-starved or actively proliferating nontransformed cells with the T-type channel blocker fails to induce morphological transformation. Thus, in addition to inhibition of the T-type channels, activation of another downstream effector(s) of Ras, which is activated by all the Ras effector domain mutants examined in this study, appears to be required for induction of morphological transformation.

The actin cytoskeleton is known to play a major role in regulation of cell morphology. It has recently been shown that Rho and Rac proteins, both of which are targeted by activated Ras, are involved in actin organization. Rho is required for regulation of the assembly of actin stress fibers and focal adhesions (67), and Rac1 is necessary for the formation of membrane ruffles (68). Our present findings of the involvement of the MAPK pathway in blocking T-type Ca2+ channel activity, which results in the induction of a spindle-shape morphology, demonstrates that morphological transformation by Ras is achieved by an integration of events imposed by multiple downstream pathways of Ras.

It remains to be elucidated how activation of the MAPK pathway inhibits T-type Ca2+ channels. The several regulatory mechanisms of L-type channel activity have been proposed. For example, direct phosphorylation of the pore-forming subunit of the L-type channel by protein kinase C, protein kinase A, as well as calmodulin kinase II have been reported (69-71) and is predicted to modulate the activity of L-type channels (72, 73). Accessory subunits also regulate the activity of L-type channels via an allosteric mechanism as well as by chaperoning the pore-forming subunit (Ref. 74, also reviewed in Ref. 75). However, little is known about regulatory mechanisms of T-type channels, and in fact, cDNA of the T-type channel has just recently been cloned (56, 76). There are several potential mechanisms that may explain how activation of the MAPK pathway inhibits T-type channels. MAPK is known to regulate the transcription of a variety of genes through direct phosphorylation of major transcription factors, including ELK-1, Sap1, bZIP, ATFa, ATF2, Net/Erp/Sap2, AP-1, c-Jun, Fos, Fra1, Fra2 and c-Myc (for reviews, see Refs. 59 and 66). Thus, MAPK may inhibit T-type Ca2+ channels in Swiss 3T3 cells by modulating the expression of the T-type channel itself or accessory proteins (at present, it is not known whether the T-type channel is a multisubunit complex or a single subunit). Alternatively, MAPK may directly inactivate T-type channels through phosphorylation. Indeed, there are two MAPK phosphorylation consensus sites in the C-terminal region of the T-type channel. These questions are currently under investigation in our laboratory. Because alteration of cell morphology is a critical event for cells to acquire a metastatic phenotype, the protocols that are designed to re-establish the proper T-type Ca2+ channel activity may prove to be effective in cancer chemotherapy.

    ACKNOWLEDGEMENTS

We thank Dr. N. Ahn for a MEK plasmid and Dr. K. Vousden for a p53 plasmid. We also thank P. Carroll for technical assistance and M. Strobeck and H. Horn for helpful discussion and critical reading of this manuscript.

    FOOTNOTES

* This work was supported in part by the American Heart Association Ohio-West Virginia Affiliate Postdoctoral Fellowship SW-97-35-F (to H. Y.), by a grant from the Naito Foundation (to H. Y.), by National Institutes of Health Grant PO1 HL22619-19 (to A. S.), and by the American Cancer Society (to K. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Cell Biology, University of Cincinnati College of Medicine, P. O. Box 670521, Cincinnati, OH 45267-0521. Tel.: 513-558-4939; Fax: 513-558-4454; E-mail: fukasak{at}emailuc.edu.

    ABBREVIATIONS

The abbreviations used are: MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; FBS, fetal bovine serum; HA, hemagglutinin; PBS, phosphate-buffered saline; pF, picofarads.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Andersson, P. (1980) Adv. Cancer Res. 33, 109-161[Medline] [Order article via Infotrieve]
  2. Weeds, A. (1982) Nature 296, 811-816[Medline] [Order article via Infotrieve]
  3. Stossel, T. P., Chaponnier, C., Ezzell, R. M., Hartwig, J. H., Janmey, P. A., Kwiztkowski, D. J., Lind, S. E., Southwick, F. S., Yin, H. L., and Zaner, K. S. (1985) Annu. Rev. Cell Biol. 1, 353-402[CrossRef]
  4. Pollard, T. D., and Cooper, J. A. (1986) Annu. Rev. Biochem. 55, 987-1035[CrossRef][Medline] [Order article via Infotrieve]
  5. Yin, H. L., Zaner, K. S., and Stossel, T. P. (1980) J. Biol. Chem. 255, 9494-9500[Abstract/Free Full Text]
  6. Burridge, K., and Feramisco, J. R. (1981) Nature 294, 565-567[Medline] [Order article via Infotrieve]
  7. Kretsinger, R. (1980) Crit. Rev. Biochem. 8, 119-174[Medline] [Order article via Infotrieve]
  8. Rasmussen, C., and Means, A. R. (1992) Cell Motil. Cytoskeleton 21, 45-57[Medline] [Order article via Infotrieve]
  9. Mooseker, M. S. (1985) Annu. Rev. Cell Biol. 1, 209-241[CrossRef]
  10. Louvard, D. (1989) Curr. Opin. Cell Biol. 1, 51-57[Medline] [Order article via Infotrieve]
  11. Franck, Z., Footer, M., and Bretscher, A. (1990) J. Cell Biol. 111, 2475-2485[Abstract]
  12. Chen, C., Corbley, M. J., Roberts, T. M., and Hess, P. (1988) Science 239, 1024-1026[Medline] [Order article via Infotrieve]
  13. Peres, A., Zippel, R., Sturani, E., and Mostacciuolo, G. (1988) Pfluegers Arch. 411, 554-557[Medline] [Order article via Infotrieve]
  14. Bean, B. P. (1989) Annu. Rev. Physiol. 51, 367-384[CrossRef][Medline] [Order article via Infotrieve]
  15. Tsien, R. W., Ellinor, P. T., and Horne, W. A. (1991) Trends Pharmacol. Sci. 12, 349-354[CrossRef][Medline] [Order article via Infotrieve]
  16. Varadi, G., Mori, Y., Mikala, G., and Schwartz, A. (1995) Trends Pharmacol. Sci. 16, 43-49[CrossRef][Medline] [Order article via Infotrieve]
  17. Jones, S. W. (1998) J. Bioenerg. Biomembr. 30, 299-312[CrossRef][Medline] [Order article via Infotrieve]
  18. Bean, B. P., and McDonough, S. I. (1998) Neuron 20, 825-828[Medline] [Order article via Infotrieve]
  19. Perez-Reyes, E. (1998) J. Bioenerg. Biomembr. 30, 313-318[CrossRef][Medline] [Order article via Infotrieve]
  20. Okada, Y., Doida, Y., Roy, G., Tsuchiya, W., Inouye, K., and Inouye, A. (1977) J. Membr. Biol. 35, 319-335[Medline] [Order article via Infotrieve]
  21. Ueda, S., Oriki, S., and Okada, Y. (1986) J. Membr. Biol. 91, 65-72[Medline] [Order article via Infotrieve]
  22. Barbacid, M. (1987) Annu. Rev. Biochem. 56, 779-827[CrossRef][Medline] [Order article via Infotrieve]
  23. Bollag, G., and McCormick, F. (1991) Annu. Rev. Cell Biol. 7, 601-632[CrossRef]
  24. Khosravi-Far, R., Campbell, S., Rossman, K. L., and Der, C. J. (1998) Adv. Cancer Res. 72, 57-107[Medline] [Order article via Infotrieve]
  25. Vojtek, A. B., and Der, C. J. (1998) J. Biol. Chem. 273, 19925-19928[Free Full Text]
  26. Van Aelst, L., Barr, M., Marcus, S., Polverino, A., and Wigler, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6213-6217[Abstract]
  27. Zhang, X. F., Settleman, J., Kyriakis, J. M., Takeuchi-Suzuki, E., Elledge, S. J., Marshall, M. S., Bruder, J. T., Rapp, U. R., and Avruch, J. (1993) Nature 6435, 308-313
  28. Warne, P. H., Viciana, P. R., and Downward, J. (1993) Nature 364, 352-355[CrossRef][Medline] [Order article via Infotrieve]
  29. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214[Medline] [Order article via Infotrieve]
  30. Moodie, S. A., and Wolfman, A. (1994) Trends Genet. 10, 14-18
  31. Morrison, D. K., and Cutler, R. E. (1997) Curr. Opin. Cell Biol. 2, 174-179[CrossRef]
  32. Crews, C. M., and Erikson, R. L. (1993) Cell 74, 215-217[Medline] [Order article via Infotrieve]
  33. Dent, P., Haser, W., Haystead, T. A. J., Vincent, L. A., Roberts, T. M., and Sturgill, T. W. (1992) Science 257, 1404-1407[Medline] [Order article via Infotrieve]
  34. Howe, L. R., Leevers, S. J., Gomez, N., Nakielny, S., Cohen, P., and Marshall, C. J. (1992) Cell 71, 335-342[Medline] [Order article via Infotrieve]
  35. Kyriakis, J. M., App, H., Zhang, X.-F., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992) Nature 358, 417-421[CrossRef][Medline] [Order article via Infotrieve]
  36. Moodie, S. A., Willumsen, B. M., Weber, M. J., and Wolfman, A. (1993) Science 260, 1658-1661[Medline] [Order article via Infotrieve]
  37. Payne, D. M., Rossomondo, A. J., Martino, P., Erickson, A. K., Her, J.-H., Shabanowitz, J., Hunt, D. F., Weber, M. J., and Sturgill, T. W. (1991) EMBO J. 10, 885-892[Abstract]
  38. Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana, P., Downward, J., and Parker, P. J. (1994) Curr. Biol. 4, 798-806[Medline] [Order article via Infotrieve]
  39. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532[CrossRef][Medline] [Order article via Infotrieve]
  40. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727-736[Medline] [Order article via Infotrieve]
  41. Klippel, A., Reinhard, C., Kavanaugh, M., Apell, G., Escobedo, M. A., and Williams, L. T. (1996) Mol. Cell. Biol. 16, 4117-4127[Abstract]
  42. Marte, B. M., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. (1997) Curr. Biol. 1, 63-70
  43. Kikuchi, A., Demo, S. D., Ye, Z-H, Chen, Y-W, and Williams, L. T. (1994) Mol. Cell. Biol. 14, 7483-7491[Abstract]
  44. Hofer, F., Fields, S., Schneider, C., and Martin, G. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11089-11093[Abstract/Free Full Text]
  45. Spaargaren, M., and Bischoff, J. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12609-12613[Abstract/Free Full Text]
  46. Jiang, H., Luo, J-Q., Urano, T., Frankel, P., Lu, Z., Foster, D. A., and Feig, L. A. (1995) Nature 378, 409-412[CrossRef][Medline] [Order article via Infotrieve]
  47. Cantor, S. B., Urano, T., and Feig, L. A. (1995) Mol. Cell. Biol. 15, 4578-4584[Abstract]
  48. White, M. A., Nicolette, C., Minden, A., Polverino, A., Van Aelst, L., Karin, M., and Wigler, M. H. (1995) Cell 80, 533-541[Medline] [Order article via Infotrieve]
  49. Joneson, T., White, M. A., Wigler, M. H., and Bar-Sagi, D. (1996) Science 271, 810-812[Abstract]
  50. Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., and Der, C. J. (1996) Mol. Cell. Biol. 16, 3923-3933[Abstract]
  51. Graham, F. L., and van der Eb, A. J. (1973) Virology 52, 456-467[Medline] [Order article via Infotrieve]
  52. Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Van Woude, G. F., and Ahn, N. G. (1994) Science 265, 966-970[Medline] [Order article via Infotrieve]
  53. Hamill, O. P., Marty, A., Nehrer, E., Sakmann, B., and Sigworth, F. J. (1981) Pfluegers Arch. 391, 85-100[Medline] [Order article via Infotrieve]
  54. Mehrke, G., Zong, X. G., Flockerzi, V., and Hoffman, F. (1994) J. Pharmacol. Exp. Ther. 271, 1483-1488[Abstract]
  55. Mishra, S. K., and Hermsmeyer, K. (1994) Circ. Res. 75, 144-148[Abstract]
  56. Cribbs, L. L., Lee, J. H., Yang, J., Satin, J., Zhang, Y., Daud, A., Barclay, J., Williamson, M. P., Fox, M., Rees, M., and Perez-Reyes, E. (1998) Circ. Res. 83, 103-109[Abstract/Free Full Text]
  57. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7686-7689[Abstract]
  58. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 27489-27494[Abstract/Free Full Text]
  59. Lewis, T. S., Shapiro, P. S., and Ahn, N. G. (1998) Adv. Cancer Res. 74, 49-139[Medline] [Order article via Infotrieve]
  60. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O., and Oren, M. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8763-8767[Abstract]
  61. Finlay, C. A., Hinds, P. W., and Levine, A. J. (1989) Cell 57, 1083-1093[Medline] [Order article via Infotrieve]
  62. Hicks, G. G., Egan, S. E., Greenberg, A. H., and Mowat, M. (1991) Mol. Cell. Biol. 11, 1344-1352[Medline] [Order article via Infotrieve]
  63. Fukasawa, K., and Vande Woude, G. F. (1997) Mol. Cell. Biol. 17, 506-518[Abstract]
  64. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. (1997) Cell 88, 593-602[CrossRef][Medline] [Order article via Infotrieve]
  65. Hille, B. (1992) Ionic Channels of Excitable Membranes, 2nd Ed., Sinauer Associates, Inc., Sunderland, MA
  66. Robinson, M. J., and Cobb, M. H. (1997) Curr. Opin. Cell Biol. 9, 180-186[CrossRef][Medline] [Order article via Infotrieve]
  67. Ridley, A. J., and Hall, A. (1992) Cell 3, 389-399
  68. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 3, 401-410
  69. Ahlijanian, M. K., Striessnig, J., and Catterall, W. A. (1991) J. Biol. Chem. 266, 20192-20197[Abstract/Free Full Text]
  70. Hell, J. W., Appleyard, S. M., Yokoyama, C. T., Warner, C., and Catterall, W. A. (1994) J. Biol. Chem. 269, 7390-7396[Abstract/Free Full Text]
  71. Hell, J. W., Yokoyama, C. T., Breeze, L. J., Chavkin, C., and Catterall, W. A. (1995) EMBO J. 14, 3036-3044[Abstract]
  72. Galizzi, J. P., Qar, J., Fosset, M., Van Renterghem, C., and Lazdunski, M. (1987) J. Biol. Chem. 262, 6947-6950[Abstract/Free Full Text]
  73. Chik, C. L.,., Li, B., Ogiwara, T., Ho, A. K., and Karpinski, E. (1996) FASEB J. 10, 1310-1317[Abstract/Free Full Text]
  74. Yamaguchi, H., Hara, M., Strobeck, M., Fukasawa, K., Schwartz, A., and Varadi, G. (1998) J. Biol. Chem. 273, 19348-19356[Abstract/Free Full Text]
  75. Catterall, W. A. (1995) Annu. Rev. Biochem. 64, 493-531[CrossRef][Medline] [Order article via Infotrieve]
  76. Perez-Reyes, E., Cribbs, L. L., Daud, A., Lacerda, A. E., Barclay, J., Williamson, M. P., Fox, M, Rees, M., and Lee, J. H. (1998) Nature 391, 896-900[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.